Moderna (NASDAQ: MRNA), an American pharmaceutical and biotechnology company, has requested that the Food and Drug Administration grant it emergency use of its Covid-19 vaccine in kids ages 12 to 17.
“We are encouraged that the Moderna COVID-19 vaccine was highly effective at preventing COVID-19 and SARS-CoV-2 infection in adolescents. We have already filed for authorization with Health Canada and the European Medicines Agency and we will file with regulatory agencies around the world for this important younger age population. We remain committed to helping to end the COVID-19 pandemic,” said Stéphane Bancel, Chief Executive Officer of Moderna.
Pfizer’s Covid vaccine was cleared for use in 12 to 15 years old last month. If approved, Moderna will facilitate a larger quantity of shots for middle and high school students before the upcoming school year. The pharmaceutical company revealed that its Covid vaccine was 100% effective on 12 to 17 year olds, during its clinical trial. Moderna’s two-dose vaccine is already authorized for use in adults.
A total of 3,700 teenagers participated in the study, according to the company. There were no cases of Covid in partakers that were given two doses of the vaccine, meanwhile four cases surged within the placebo group, the company stated.
The U.S. strives to achieve herd immunity, believed to be around 75% to 85% of the U.S., and stop the spread of the virus. With children making up about 20% of the U.S. population, the chances of reaching that goal increase. However some experts are doubtful as coronavirus variants continue to spread.
On May 28th, the Centers for Disease Control and Prevention, relaxed its health guidance within summer camps, stating that fully vaccinated teens would not need to wear masks or maintain 6 feet of distance between each other.